Hartmut Ehrlich is the founder of Abivax. Latest round: IPO. Backed by TCGX, Invus, Deep Track Capital.
Hartmut Ehrlich is the CEO of Abivax, a clinical-stage biotechnology company. He leads the company in developing novel treatments for inflammatory diseases, viral diseases, and cancer. Under his leadership, the company has secured significant financing rounds from specialist investors to advance its clinical trials.
Full founder directory · Investor directory · Company funding database · Fundraising library